Onkologie. 2010:4(3):167-171

The current view of adjuvant hormonal treatment of premenopausal patients with breast cancer

Petra Tesařová
Onkologická klinika 1. LF a VFN, Praha

Adjuvant hormonal therapy is a key component of treatment for young patients with estrogen receptor positive breast cancer, ensuring

patients a significant improvement in the chances of full health. Its right composition and sequence to other therapeutic modalities

(chemotherapy, radiotherapy, biological therapy) ensure maximum efficiency.

Keywords: breast cancer, premenopausal status, hormonal therapy, tamoxifen, goserelin

Published: July 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tesařová P. The current view of adjuvant hormonal treatment of premenopausal patients with breast cancer. Onkologie. 2010;4(3):167-171.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687.
    2. Colleoni M, Gelber S, Goldhirsch A, et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol 2006; 24: 1332. Go to original source... Go to PubMed...
    3. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial. J Natl Cancer Inst 2007; 99: 506.
    4. Albain KS, Barlow W, O'Malley F, et al. Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814) (abstract). San Antonio Breast Cancer Symposium, San Antonio, TX, December 2004 (abstract 37).
    5. Ahn SH, Son BH, Kim SW, et al. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea-a report from the Korean Breast Cancer Society. J Clin Oncol 2007; 25: 2360. Go to original source... Go to PubMed...
    6. Tamoxifen citrate product information available at DailyMed. Available online at http://dailymed.nlm.nih.gov/dailymed/about.cfm, accessed September 24, 2009.
    7. Hughes LL, Gray RJ, Solin LJ, et al. Efficacy of radiotherapy for ovarian ablation: results of a breast intergroup study. Cancer 2004; 101: 969. Go to original source... Go to PubMed...
    8. Davidson NE. Ovarian ablation as adjuvant therapy for breast cancer. J Natl Cancer Inst Monogr 2001: 67. Go to original source... Go to PubMed...
    9. Dellapasqua S, Colleoni M, Gelber RD, Goldhirsch A. Adjuvant endocrine therapy for premenopausal women with early breast cancer. J Clin Oncol 2005; 23: 1736. Go to original source... Go to PubMed...
    10. Cuzick J, Ambroisine L, Davidson N, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007; 369: 1711. Go to original source... Go to PubMed...
    11. Ejlertsen B, Mouridsen HT, Jensen MB, et al. Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer. J Clin Oncol 2006; 24: 4956. Go to original source... Go to PubMed...
    12. Jonat W, Kaufmann M, Sauerbrei W, et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 2002; 20: 4628. Go to original source... Go to PubMed...
    13. Kaufmann M, Jonat W, Blamey R, et al. Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 2003; 39: 1711. Go to original source... Go to PubMed...
    14. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy's Hospital, London. Lancet 1993; 341: 1293.
    15. Thomson CS, Twelves CJ, Mallon EA, Leake RE. Adjuvant ovarian ablation vs CMF chemotherapy in premenopausal breast cancer patients: trial update and impact of immunohistochemical assessment of ER status. Breast 2002; 11: 419. Go to original source... Go to PubMed...
    16. Castiglione-Gertsch M, O'Neill A, Price KN, et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 2003; 95: 1833. Go to original source... Go to PubMed...
    17. von Minckwitz G, Graf E, Geberth M, et al. CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93). Eur J Cancer 2006; 42: 1780. Go to original source... Go to PubMed...
    18. Schmid P, Untch M, Kosse V, et al. Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study. J Clin Oncol 2007; 25: 2509. Go to original source... Go to PubMed...
    19. Davidson NE, O'Neill AM, Vukov AM, et al. Chemoendocrine Therapy for Premenopausal Women With Axillary Lymph Node-Positive, Steroid Hormone Receptor-Positive Breast Cancer: Results From INT 0101 (E5188). J Clin Oncol 2005; 23: 5973. Go to original source... Go to PubMed...
    20. Arriagada R Le MG, Spielmann M, et al. Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann Oncol 2005; 16: 389. Go to original source... Go to PubMed...
    21. Kaufmann M, Graf E, Jonat W, et al. A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer - GABG-IV B-93. Eur J Cancer 2007; 43: 2351. Go to original source... Go to PubMed...
    22. Vanhuyse M, Fournier C, Bonneterre J. Chemotherapyinduced amenorrhea: influence on disease-free survival and overall survival in receptor-positive premenopausal early breast cancer patients. Ann Oncol 2005; 16: 1283. Go to original source... Go to PubMed...
    23. Del Mastro L, Venturini M, Sertoli MR, Rosso R. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Res Treat 1997; 43: 183. Go to original source... Go to PubMed...
    24. National Comprehensive Cancer Network (NCCN) guidelines available online at www.nccn.org/professionals/physician_gls/f_guidelines.asp (September 24, 2009).
    25. Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20: 1319. Go to original source... Go to PubMed...
    26. Love RR, Van Dinh N, Quy TT, et al. Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women. J Clin Oncol 2008; 26: 253. Go to original source... Go to PubMed...
    27. Robert NJ, Wang M, Cella D, et al. Phase III comparison of tamoxifen versus tamoxifen with ovarian ablation in premenopausal women with axillary node-negative receptorpositive breast cancer <= 3 cm (abstract). Proc Am Soc Clin Oncol 2003; 22: 5a. Go to original source...
    28. Baum M, Hackshaw A, Houghton J, et al. Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study. Eur J Cancer 2006; 42: 895. Go to original source... Go to PubMed...
    29. Hackshaw A, Baum M, Fornander T, et al. Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. J Natl Cancer Inst 2009; 101: 341. Go to original source... Go to PubMed...
    30. Roche H, Kerbrat P, Bonneterre J, et al. Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year followup results of French Adjuvant Study Group 06 randomised trial. Ann Oncol 2006; 17: 1221. Go to original source... Go to PubMed...
    31. Boccardo F, Rubagotti A, Amoroso D, et al. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 2000; 18: 2718. Go to original source... Go to PubMed...
    32. Jakesz R, Hausmaninger H, Kubista E, et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer-Austrian breast and colorectal cancer study group trial 5. J Clin Oncol 2002; 20: 4621. Go to original source... Go to PubMed...
    33. De Placido S, De Laurentiis M, De Lena M, et al. A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of nodepositive breast cancer. Br J Cancer 2005; 92: 467. Go to original source... Go to PubMed...
    34. Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial. J Natl Cancer Inst 2007; 99: 516.
    35. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360: 679. Go to original source... Go to PubMed...
    36. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Panel members Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009., Ann Oncol. 2009; 20(8): 1319-1329. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.